Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R.

MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. doi: 10.15585/mmwr.rr6901a1.

PMID:
32053584
2.

The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Ragan EJ, Kleinman MB, Sweigart B, Gnatienko N, Parry CD, Horsburgh CR, LaValley MP, Myers B, Jacobson KR.

Int J Tuberc Lung Dis. 2020 Jan 1;24(1):73-82. doi: 10.5588/ijtld.19.0080.

PMID:
32005309
3.

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B.

Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. Erratum in: Am J Respir Crit Care Med. 2020 Feb 15;201(4):500-501.

4.

Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.

Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ.

Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201908-1606OC. [Epub ahead of print]

PMID:
31711306
5.

Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.

Reddy KP, Horsburgh CR, Wood R, Fields NF, Girouard MP, Costantini S, Hou T, Freedberg KA, Walensky RP.

Ann Am Thorac Soc. 2020 Feb;17(2):202-211. doi: 10.1513/AnnalsATS.201905-418OC.

PMID:
31689133
6.

Partitioning the risk of tuberculosis transmission in household contact studies.

McIntosh AI, Jenkins HE, Horsburgh CR, Jones-López EC, Whalen CC, Gaeddert M, Marques-Rodrigues P, Ellner JJ, Dietze R, White LF.

PLoS One. 2019 Oct 22;14(10):e0223966. doi: 10.1371/journal.pone.0223966. eCollection 2019.

7.

Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.

Bouton TC, de Vos M, Ragan EJ, White LF, Van Zyl L, Theron D, Horsburgh CR, Warren RM, Jacobson KR.

PLoS One. 2019 Oct 17;14(10):e0223308. doi: 10.1371/journal.pone.0223308. eCollection 2019.

8.

Progress in global rollout of new multidrug-resistant tuberculosis treatments.

Held K, McAnaw S, Chiang CY, Trebucq A, Horsburgh CR.

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):996-999. doi: 10.5588/ijtld.19.0826.

PMID:
31615606
9.

Management of drug-resistant tuberculosis.

Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr.

Lancet. 2019 Sep 14;394(10202):953-966. doi: 10.1016/S0140-6736(19)31882-3. Review.

PMID:
31526739
10.

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Stout JE, Sterling TR, Horsburgh CR Jr.

N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. No abstract available.

PMID:
31509689
11.

Interaction of nutritional status and diabetes on active and latent tuberculosis: a cross-sectional analysis.

Kubiak RW, Sarkar S, Horsburgh CR, Roy G, Kratz M, Reshma A, Knudsen S, Salgame P, Ellner JJ, Drain PK, Hochberg NS.

BMC Infect Dis. 2019 Jul 16;19(1):627. doi: 10.1186/s12879-019-4244-4.

12.

"Plus Ça Change…".

Horsburgh CR.

Clin Infect Dis. 2019 Jul 2. pii: ciz575. doi: 10.1093/cid/ciz575. [Epub ahead of print] No abstract available.

PMID:
31265722
13.

Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies.

Martinez L, Lo NC, Cords O, Hill PC, Khan P, Hatherill M, Mandalakas A, Kay A, Croda J, Horsburgh CR, Zar HJ, Andrews JR.

Lancet Respir Med. 2019 Jun;7(6):544-552. doi: 10.1016/S2213-2600(19)30137-7. Epub 2019 May 8. Review.

PMID:
31078497
14.

Detection, survival and infectious potential of Mycobacterium tuberculosis in the environment: a review of the evidence and epidemiological implications.

Martinez L, Verma R, Croda J, Horsburgh CR Jr, Walter KS, Degner N, Middelkoop K, Koch A, Hermans S, Warner DF, Wood R, Cobelens F, Andrews JR.

Eur Respir J. 2019 Jun 27;53(6). pii: 1802302. doi: 10.1183/13993003.02302-2018. Print 2019 Jun. Review.

PMID:
31048345
15.

Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay.

Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):358-362. doi: 10.5588/ijtld.16.0837.

16.

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine.

Chiang SS, Sheremeta Y, Padilla RS, Jenkins HE, Horsburgh CR Jr, Petrenko V, Rybak NR.

J Epidemiol Glob Health. 2019 Mar;9(1):56-61. doi: 10.2991/jegh.k.190225.002.

17.

Effect of malnutrition on radiographic findings and mycobacterial burden in pulmonary tuberculosis.

Hoyt KJ, Sarkar S, White L, Joseph NM, Salgame P, Lakshminarayanan S, Muthaiah M, Vinod Kumar S, Ellner JJ, Roy G, Horsburgh CR Jr, Hochberg NS.

PLoS One. 2019 Mar 27;14(3):e0214011. doi: 10.1371/journal.pone.0214011. eCollection 2019.

18.

Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.

Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B.

J Hepatol. 2019 Jul;71(1):62-70. doi: 10.1016/j.jhep.2019.02.011. Epub 2019 Feb 21.

PMID:
30797050
19.

Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study.

Reddy KP, Gupta-Wright A, Fielding KL, Costantini S, Zheng A, Corbett EL, Yu L, van Oosterhout JJ, Resch SC, Wilson DP, Horsburgh CR Jr, Wood R, Alufandika-Moyo M, Peters JA, Freedberg KA, Lawn SD, Walensky RP.

Lancet Glob Health. 2019 Feb;7(2):e200-e208. doi: 10.1016/S2214-109X(18)30436-4.

20.

Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and Completion.

Lambert LA, Katz D, Feng PJ, Djojonegoro BM, Fair E, Jasuja S, Marantz S, Horsburgh CR Jr, Ho C.

Microbiol Insights. 2018 Nov 27;11:1178636118811311. doi: 10.1177/1178636118811311. eCollection 2018.

21.

Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

van der Heijden YF, Abdullah F, Andrade BB, Andrews JR, Christopher DJ, Croda J, Ewing H, Haas DW, Hatherill M, Horsburgh CR Jr, Mave V, Nakaya HI, Rolla V, Srinivasan S, Sugiyono RI, Ugarte-Gil C, Hamilton C.

Tuberculosis (Edinb). 2018 Dec;113:153-162. doi: 10.1016/j.tube.2018.09.009. Epub 2018 Oct 1.

22.

Undernutrition and Tuberculosis: Public Health Implications.

Sinha P, Davis J, Saag L, Wanke C, Salgame P, Mesick J, Horsburgh CR, Hochberg NS.

J Infect Dis. 2019 Apr 16;219(9):1356-1363. doi: 10.1093/infdis/jiy675. Review.

PMID:
30476125
23.

Insights into drug-resistant tuberculosis treatment: results of The Union DR-TB Working Group Survey, 2017.

Mezwa K, McAnaw S, Chiang CY, Trébucq A, Horsburgh CR.

Public Health Action. 2018 Sep 21;8(3):141-144. doi: 10.5588/pha.18.0022.

24.

Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.

Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, Parry CDH, Horsburgh CR, Warren RM, Jacobson KR.

BMC Infect Dis. 2018 Sep 29;18(1):488. doi: 10.1186/s12879-018-3396-y.

25.

Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.

Yuengling KA, Padayatchi N, Wolf A, Mathema B, Brown T, Horsburgh CR, OʼDonnell MR.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):474-480. doi: 10.1097/QAI.0000000000001833.

26.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

27.

FDG-PET/CT activity leads to the diagnosis of unsuspected TB: a retrospective study.

Geadas C, Acuna-Villaorduna C, Mercier G, Kleinman MB, Horsburgh CR Jr, Ellner JJ, Jacobson KR.

BMC Res Notes. 2018 Jul 13;11(1):464. doi: 10.1186/s13104-018-3564-6.

28.

In reply.

Saag LA, Horsburgh CR.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):968. doi: 10.5588/ijtld.18.0272-2. No abstract available.

PMID:
29991411
29.

Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?

Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):358-362. doi: 10.5588/ijtld.17.0837.

30.

Quantifying TB transmission: a systematic review of reproduction number and serial interval estimates for tuberculosis.

Ma Y, Horsburgh CR, White LF, Jenkins HE.

Epidemiol Infect. 2018 Sep;146(12):1478-1494. doi: 10.1017/S0950268818001760. Epub 2018 Jul 4.

31.

Nontuberculous Mycobacteria and Testing for Latent Tuberculosis Infection.

von Reyn CF, Horsburgh CR.

Clin Infect Dis. 2018 Sep 28;67(8):1308. doi: 10.1093/cid/ciy290. No abstract available.

PMID:
29912296
32.

MDR-TB in children: back to the basics.

Horsburgh CR, Gupta A.

Int J Tuberc Lung Dis. 2018 May 1;22(5):1-2. doi: 10.5588/ijtld.17.0834. No abstract available.

PMID:
29665946
33.

Pan-tuberculosis regimens: an argument against.

Dheda K, Gumbo T, Lange C, Horsburgh CR Jr, Furin J.

Lancet Respir Med. 2018 Apr;6(4):240-242. doi: 10.1016/S2213-2600(18)30097-3. No abstract available.

PMID:
29595502
34.

Low body mass index and latent tuberculous infection: a systematic review and meta-analysis.

Saag LA, LaValley MP, Hochberg NS, Cegielski JP, Pleskunas JA, Linas BP, Horsburgh CR.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):358-365. doi: 10.5588/ijtld.17.0558.

PMID:
29562981
35.

Existing blood transcriptional classifiers accurately discriminate active tuberculosis from latent infection in individuals from south India.

Leong S, Zhao Y, Joseph NM, Hochberg NS, Sarkar S, Pleskunas J, Hom D, Lakshminarayanan S, Horsburgh CR Jr, Roy G, Ellner JJ, Johnson WE, Salgame P.

Tuberculosis (Edinb). 2018 Mar;109:41-51. doi: 10.1016/j.tube.2018.01.002. Epub 2018 Jan 31.

PMID:
29559120
36.

Has compassionate use ever sunk a drug?

McAnaw S, Rodriguez CA, Muller A, Mitnick C, Horsburgh CR.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):119-120. doi: 10.5588/ijtld.17.0793. No abstract available.

PMID:
29506605
37.

Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.

Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):405-412. doi: 10.1097/QAI.0000000000001610.

38.

Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.

Rohr JK, Ive P, Horsburgh CR, Berhanu R, Hoffmann CJ, Wood R, Boulle A, Giddy J, Prozesky H, Vinikoor M, Mwanza MW, Wandeler G, Davies MA, Fox MP.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):413-416. doi: 10.1097/QAI.0000000000001611.

39.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

40.

Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital.

Assoumou SA, Huang W, Young K, Horsburgh CR, Linas BP.

J Health Care Poor Underserved. 2017;28(4):1333-1344. doi: 10.1353/hpu.2017.0118.

41.

Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.

Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR Jr, Marks SM, Linas BP.

JAMA Intern Med. 2017 Dec 1;177(12):1755-1764. doi: 10.1001/jamainternmed.2017.3941.

42.

Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP.

Clin Infect Dis. 2018 Jan 18;66(3):376-384. doi: 10.1093/cid/cix798.

43.

Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India: Opportunities for intervention.

Hochberg NS, Sarkar S, Horsburgh CR Jr, Knudsen S, Pleskunas J, Sahu S, Kubiak RW, Govindarajan S, Salgame P, Lakshminarayanan S, Sivaprakasam A, White LF, Joseph NM, Ellner JJ, Roy G.

PLoS One. 2017 Aug 23;12(8):e0183195. doi: 10.1371/journal.pone.0183195. eCollection 2017.

44.

Predictors of delayed care seeking for tuberculosis in southern India: an observational study.

Van Ness SE, Chandra A, Sarkar S, Pleskunas J, Ellner JJ, Roy G, Lakshminarayanan S, Sahu S, Horsburgh CR Jr, Jenkins HE, Hochberg NS.

BMC Infect Dis. 2017 Aug 15;17(1):567. doi: 10.1186/s12879-017-2629-9.

45.

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1.

Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY.

Open Forum Infect Dis. 2016 Dec 27;4(1):ofw266. doi: 10.1093/ofid/ofw266. eCollection 2017 Winter.

46.

Latent Tuberculosis Infection Testing Practices in Long-Term Care Facilities, Boston, Massachusetts.

Reddy D, Walker J, White LF, Brandeis GH, Russell ML, Horsburgh CR Jr, Hochberg NS.

J Am Geriatr Soc. 2017 Jun;65(6):1145-1151. doi: 10.1111/jgs.14696. Epub 2017 May 3.

PMID:
28467605
47.

Increased risk of active tuberculosis after cancer diagnosis.

Simonsen DF, Farkas DK, Horsburgh CR, Thomsen RW, Sørensen HT.

J Infect. 2017 Jun;74(6):590-598. doi: 10.1016/j.jinf.2017.03.012. Epub 2017 Mar 31.

PMID:
28366685
48.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
49.

Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting.

Horsburgh CR, Rusen ID, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):1-3. doi: 10.5588/ijtld.16.0568. No abstract available.

PMID:
28240564
50.

Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial.

Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):286-296. doi: 10.5588/ijtld.16.0469. Epub 2017 Jan 13.

Supplemental Content

Loading ...
Support Center